Application Note

Rapid, Sensitive Cancer Biomarker Screening In cfDNA

By Anna Quinlan and Dawne Shelton

Oncology

Disease-associated mutations, especially those linked to cancer, can be prognostic of outcome and inform treatment choices. Traditional tissue biopsies, however, limit our ability to implement such personalized treatments. These invasive surgical procedures can be used to genotype a tumor prior to treatment, but they are not amenable to serial tracking of treatment efficacy or disease progression. Furthermore, for some cancers, such as metastatic breast or prostate cancer, or for tumors that are not easily accessible, tissue biopsies can prove impossible.

By using cell-free DNA (cfDNA) to quantify cancer markers in blood or other bodily fluids, liquid biopsies can eliminate the need for invasive surgical procedures. However, the most commonly used approaches to quantify cfDNA, next-generation sequencing (NGS) and quantitative real-time PCR (RT-qPCR), have their own challenges.

VIEW THE APPLICATION NOTE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Cell & Gene? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: